Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, International, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BL0020 as A Single Agent in Patients With Advanced Solid Tumors

NCT05886868 is registered in ClinicalTrials.gov with Shanghai Best-Link Bioscience, LLC as lead sponsor.

NCT NCT05886868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05886868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, International, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BL0020 as A Single Agent in Patients With Advanced Solid Tumors
Lead sponsor
Shanghai Best-Link Bioscience, LLC
Phase
Phase 1
Overall status
Unknown status
Start date
October 24, 2023
Completion date
February 28, 2025
Enrollment
66 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor